Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Pegtibatinase som en enzymterapi for pasienter med homocystinuri forårsaket av cystationin beta-syntase-mangel (COMPOSE)

5. august 2026 oppdatert av: Travere Therapeutics, Inc.

En dobbeltblind, randomisert, placebokontrollert, fase 1/2-studie for å vurdere sikkerhet, tolerabilitet, farmakokinetikk, farmakodynamikk og effekter på kliniske utfall av Pegtibatinase (TVT-058), administrert subkutant hos pasienter med cystationin beta-syntase-deficient homocystinuria (KOMPOSISER)

Homocystinuri forårsaket av Cystationine Beta-Syntase (CBS) mangel er en sjelden autosomal-recessiv metabolsk tilstand karakterisert ved et overskudd av homocystein (Hcy) i plasma, vev og urin. Det skyldes redusert eller fraværende aktivitet av CBS-enzymet, og er også kjent som klassisk homocystinuri. Symptomene assosiert med homocystinuri varierer i alvorlighetsgrad og tidspunkt for debut mellom pasienter. Noen berørte individer kan ha milde tegn på lidelsen; andre kan ha multisystemisk involvering inkludert potensielt livstruende komplikasjoner. Homocystinuri kan påvirke mange forskjellige organsystemer i kroppen; de fire mest involverte er øynene, sentralnervesystemet, skjelettet og det vaskulære systemet.

De nåværende tilnærmingene til behandling av homocystinuripasienter inkluderer et svært restriktivt kosthold og bruk av kosttilskudd. Livstidsoverholdelse av denne dietten er dårlig. Pegtibatinase (TVT-058) representerer en ny terapeutisk tilnærming som inkorporerer bruken av en modifisert versjon av det naturlige, humane CBS (hCBS) enzymet. Målet med behandlingen er å introdusere CBS-enzymet i sirkulasjonen, noe som resulterer i reduserte Hcy-nivåer, økte cystationin (Cth) og cystein (Cys) nivåer.

Studieoversikt

Status

Rekruttering

Forhold

Intervensjon / Behandling

Detaljert beskrivelse

Primary Objective - Cohorts 1-6

Researchers are performing this study to learn if pegtibatinase is safe and tolerable (how it makes participants feel).

Researchers will use medical examination, blood tests, and urine tests to measure side effects (unwanted health problems that may or may not be related to the study treatment), changes in laboratory tests and in the electrical activity of the heart (as measured by electrocardiogram or "ECG"), and if the body makes antibodies to fight against pegtibatinase. Antibodies are proteins that the body makes that may stop pegtibatinase from working or may cause side effects.

Secondary Objectives - Cohorts 1-6

Researchers also want to learn about:

  • What are the levels of pegtibatinase in the body after single and repeated doses?
  • How does pegtibatinase affect levels of certain substances that are produced when the body breaks down and creates homocysteine?
  • What are the effects of pegtibatinase on the eyes, bones, mental health, and cognitive function? Researchers will use blood tests, physical examinations, and questionnaires to answer these questions.

Cohort 7 Objectives

Group 7 is open to children aged 5 to 11 years old (or "pediatric participants") who meet the requirements for the study.

Researchers are performing this part of the study with Group 7 to learn if pegtibatinase is safe and tolerable (how it makes participants feel) and if it increases antibody levels when it is given to children with HCU.

Researchers will use blood tests and physical examinations to measure side effects that happen during the study, changes in laboratory tests, electrical activity of the heart, antibody levels, vital signs, and the number of pediatric participants that have too high or too low levels of methionine. Researchers will use questionnaires to measure the number of pediatric participants that need more protein in their diet.

Researchers are performing this part of the study with Group 7 because they also want to learn about:

  • What are the levels of pegtibatinase in the pediatric participant's body after single and repeated doses?
  • How does pegtibatinase affect levels of total homocysteine and methionine in the pediatric participant's body? Researchers will use blood tests to answer these questions.

Study Population and Treatments

This study will include children and adults from 5 to 65 years old with HCU. Participants in Groups 1 to 6 were aged 12 to 65 years old, and Group 7 participants will be aged 5 to 11 years old. Participants in the study will take their standard of care treatment.

Groups 1 to 6 have completed this study already. For these groups, 24 participants aged 12 to 65 years old who met the requirements of the study were split into 1 of the 6 groups. For each group, 3 participants were chosen to take pegtibatinase for every 1 participant chosen to take an injection that does not have any medicine in it (or "placebo"). Participants were assigned to pegtibatinase or placebo by chance, like the flip of a coin. This is called "randomization". Neither the researchers nor the participants knew which treatment they were getting until the study was completed. This is known as a "double-blind" approach.

Group 7 is open and will be conducted globally. It will include 10 to 15 pediatric participants aged 5 to 11 years old who meet the requirements of the study. All participants in this group will receive pegtibatinase. All participants will know that this is the treatment that they receive. This is called an "open label" approach. The treatment period will be separated into 3 parts: Part A, Part B, and Part C. Each part will test a different dose of pegtibatinase. After each part, pediatric participants who meet specific requirements will move to the next part. If the pediatric participants do not meet specific requirements to move to the next part, they will have the option to join the ENSEMBLE study (NCT06431893) and continue taking that same dose.

Pegtibatinase or placebo will be given as an injection under the skin (or "subcutaneous injection"). Doses for each group are shown below.

  • Group 1: 0.33 mg/kg pegtibatinase or placebo 1 time a week.
  • Group 2: 0.66 mg/kg pegtibatinase or placebo 1 time a week.
  • Group 3: 1.0 mg/kg pegtibatinase or placebo 1 time a week.
  • Group 4: 1.0 mg/kg pegtibatinase or placebo 2 times a week.
  • Group 5: 1.5 mg/kg pegtibatinase or placebo 2 times a week.
  • Group 6: 2.5 mg/kg pegtibatinase or placebo 2 times a week.
  • Group 7:
  • Part A: 1.0 mg/kg pegtibatinase 2 times a week for 8 weeks;
  • Part B: 1.5 mg/kg pegtibatinase 2 times a week for 8 weeks;
  • Part C: 2.5 mg/kg pegtibatinase 2 times a week for 4 weeks.

Study Duration and Visits

Participants in Groups 1 to 6 were in the study for up to 158 weeks, including the screening period of up to 8 weeks, a double-blind treatment period of up to 12 weeks, and an extension period of up to 138 weeks. A continuation study called ENSEMBLE was available to participants. Participants were offered to join the ENSEMBLE study before they finished the extension period of the COMPOSE study.

Pediatric participants in Group 7 may be in the study for up to 42 weeks, including the screening period of up to 10 weeks, open-label treatment period of up to 20 weeks, and up to 12 weeks of additional treatment at the same dose if the ENSEMBLE study is not yet open.

If participants in Group 7 meet all the requirements of the study, they will have up to 53 visits to a study center or at home. If the ENSEMBLE study is not yet open at their site, they can have up to 23 more visits to continue treatment.

These visits can include:

  • Blood and urine tests
  • Physical examinations
  • Questionnaires
  • Injections
  • Questions about how they are feeling or any problems they are having

Safety / Adverse Events

Researchers will keep track of any medical problems that a participant has during a study (or "adverse event"). All participants in this study will have regular laboratory tests, health checkups, and site visits to watch for health risks and measure safety.

Benefit-Risk Conclusion Researchers have worked to reduce risks to participants in this study. They believe the risks of taking pegtibatinase in this study are justified by the potential benefits that they think pegtibatinase may have for people with HCU.

Studietype

Intervensjonell

Registrering (Antatt)

39

Fase

  • Fase 2
  • Fase 1

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studiesteder

    • Colorado
      • Aurora, Colorado, Forente stater, 80045
        • Fullført
        • Travere Investigational Site
    • Florida
      • Miami, Florida, Forente stater, 33136
        • Fullført
        • Travere Investigational Site
    • Illinois
      • Chicago, Illinois, Forente stater, 60611
        • Har ikke rekruttert ennå
        • Ann & Robert H. Lurie Children's Hospital of Chicago
    • Indiana
      • Indianapolis, Indiana, Forente stater, 46202
        • Fullført
        • Travere Investigational Site
    • Maine
      • Portland, Maine, Forente stater, 04102
        • Fullført
        • Travere Investigational Site
    • Massachusetts
      • Boston, Massachusetts, Forente stater, 02115
        • Fullført
        • Travere Investigational Site
    • New York
      • New York, New York, Forente stater, 10029
        • Har ikke rekruttert ennå
        • The Mount Sinai Hospital
      • New York, New York, Forente stater, 10029
        • Fullført
        • Travere Investigational Site
    • North Carolina
      • Morrisville, North Carolina, Forente stater, 27560
        • Rekruttering
        • Science 37 - Virtual Site
    • Pennsylvania
      • Philadelphia, Pennsylvania, Forente stater, 19104
        • Fullført
        • Travere Investigational Site
      • Paris, Frankrike, 75015
        • Har ikke rekruttert ennå
        • Hospital Necker-Enfants Malades, Neurologie Pediatrique
      • Doha, Qatar
        • Har ikke rekruttert ennå
        • Sidra Medicine

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

12 år til 65 år (Barn, Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Beskrivelse

Inklusjonskriterier:

  • Bekreftet diagnose av homocystinuri basert på genetisk bekreftelse og plasma tHcy ≥50 mikromol og dokumentasjon av tidligere tHcy nivå ≥80 mikromol
  • Villig og i stand til å gi skriftlig, signert informert samtykke og overholde alle studierelaterte prosedyrer.
  • Forsøkspersoner født biologisk som kvinner som er i fertil alder må ha en negativ graviditetstest ved screening og være villige til å ta ytterligere graviditetstester i løpet av studien. Personer født biologisk som menn som identifiserer seg som kvinner og ikke er i fertil alder, trenger ikke å gjennomgå graviditetstester
  • Seksuelt aktive forsøkspersoner som har fruktbar evne eller de som har partnere i fertil alder, må være villige til å bruke akseptable prevensjonsmetoder mens de er på studien og i 4 uker etter avsluttet studie
  • Villig til å opprettholde et stabilt kosthold uten vesentlige endringer mens du studerer og fullføre en daglig diettdagbok.

Ekskluderingskriterier:

  • Tidligere eksponering for pegtibatinase og/eller tidligere deltagelse i en klinisk studie som inkluderte administrering av pegtibatinase
  • Bruk av ethvert undersøkelsesprodukt eller medisinsk utstyr innen 30 dager før screening, eller under undersøkelse
  • Bruk eller planlagt bruk av injiserbare legemidler som inneholder PEG (annet enn pegtibatinase eller COVID-19-vaksiner), inkludert medroxyprogesteron (f.eks. Depo-Provera) injeksjon, innen 3 måneder før screening og under studiedeltakelse
  • Kjent overfølsomhet overfor PEG-holdig produkt eller komponenter av pegtibatinase
  • En positiv test for HIV-antistoff, hepatitt B-overflateantigen eller hepatitt C-antistoff
  • En historie med organtransplantasjon, kronisk immunsuppressiv terapi eller rusmisbruk
  • Gravid eller ammer ved screening eller planlegger å bli gravid (selv eller partner) eller å amme når som helst i løpet av studien
  • Samtidig sykdom eller tilstand eller planlagt større operasjon som ville forstyrre studiedeltakelsen eller sikkerheten etter etterforskerens oppfatning.
  • Enhver tilstand som, etter etterforskerens syn, setter forsøkspersonen i høy risiko for dårlig behandlingssamsvar eller for ikke å fullføre studien
  • Planlagt større operasjon i studieperioden

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Firemannsrom

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Aktiv komparator: Pegtibatinase (Cohort 1-6)
Double-Blind Treatment Cohorts (≥12 to ≤65 years)
Pegtibatinase steril oppløsning for subkutan injeksjon
Andre navn:
  • TVT-058
  • OT-58
  • PEG modifisert CBS, PEG htCBS C15S, htCBS C15S ME-200GS
Placebo komparator: Placebo (Cohort 1-6)
Double-Blind Treatment Cohorts (≥12 to ≤65 years)
Normal saltvann for subkutan injeksjon
Eksperimentell: Pegtibatinase (Cohort 7)
Pediatric Open-label Treatment Cohort (≥5 to <12 years)
Pegtibatinase steril oppløsning for subkutan injeksjon
Andre navn:
  • TVT-058
  • OT-58
  • PEG modifisert CBS, PEG htCBS C15S, htCBS C15S ME-200GS

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Incidence of AEs
Tidsramme: • Cohorts 1-6: Through double-blind study completion, approximately 10 months per patient • Cohort 7: First dose through End of Treatment (up to 32 weeks)
Incidence of AEs (by type, severity and relationship to study drug)
• Cohorts 1-6: Through double-blind study completion, approximately 10 months per patient • Cohort 7: First dose through End of Treatment (up to 32 weeks)
Anti-pegtibatinase antibodies
Tidsramme: • Cohorts 1-6: Through double-blind study completion, approximately 10 months per patient • Cohort 7: First dose through End of Treatment (up to 32 weeks)
Presence and levels of anti-pegtibatinase antibodies in plasma as measured by antibody titers
• Cohorts 1-6: Through double-blind study completion, approximately 10 months per patient • Cohort 7: First dose through End of Treatment (up to 32 weeks)
Anti-PEG antibodies
Tidsramme: • Cohorts 1-6: Through double-blind study completion, approximately 10 months per patient • Cohort 7: First dose through End of Treatment (up to 32 weeks)
Presence and levels of anti-PEG antibodies in plasma as measured by antibody titers
• Cohorts 1-6: Through double-blind study completion, approximately 10 months per patient • Cohort 7: First dose through End of Treatment (up to 32 weeks)
Incidence of hypermethioninemia (Cohort 7 only)
Tidsramme: First dose through End of Treatment (up to Week 32)
The number and percentage of participants who develop hypermethioninemia during treatment, based on plasma methionine concentrations exceeding the protocol-defined threshold. Participants meeting the protocol-defined threshold may undergo dietary management or study treatment modifications, as appropriate.
First dose through End of Treatment (up to Week 32)
Incidence of hypomethioninemia (Cohort 7 only)
Tidsramme: First dose through End of Treatment (up to Week 32)
The number and percentage of participants who develop hypomethioninemia during treatment, based on plasma methionine concentrations below the protocol-defined threshold. Participants meeting the protocol-defined threshold may receive dietary protein supplementation or study treatment modifications, as appropriate.
First dose through End of Treatment (up to Week 32)
The proportion of participants requiring dietary protein rescue (Cohort 7 only)
Tidsramme: First dose through End of Treatment (up to Week 32)
The proportion of participants who require initiation of dietary protein supplementation during study treatment to manage protocol-defined low plasma methionine concentrations.
First dose through End of Treatment (up to Week 32)

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Changes in pegtibatinase levels
Tidsramme: • Cohorts 1-6: Through double-blind study completion, approximately 10 months per patient • Cohort 7: First dose through End of Treatment (up to 32 weeks)
Changes in pegtibatinase levels following single and repeat administration at specified timepoints
• Cohorts 1-6: Through double-blind study completion, approximately 10 months per patient • Cohort 7: First dose through End of Treatment (up to 32 weeks)
Changes in Met cycle metabolites levels - tHcy
Tidsramme: • Cohorts 1-6: Through double-blind study completion, approximately 10 months per patient • Cohort 7: First dose through End of Treatment (up to 32 weeks)
Changes in total homocysteine levels in micromoles
• Cohorts 1-6: Through double-blind study completion, approximately 10 months per patient • Cohort 7: First dose through End of Treatment (up to 32 weeks)
Changes in Met cycle metabolites levels - total Cys (Cohorts 1-6 Only)
Tidsramme: Through double-blind study completion, approximately 10 months per patient
Changes in total cysteine levels in micromoles
Through double-blind study completion, approximately 10 months per patient
Changes in Met cycle metabolites levels - Me (Cohorts 1-6 Only)
Tidsramme: Through double-blind study completion, approximately 10 months per patient
Changes in methionine levels in micromoles
Through double-blind study completion, approximately 10 months per patient
Changes in Met cycle metabolites levels - Cth (Cohorts 1-6 Only)
Tidsramme: Through double-blind study completion, approximately 10 months per patient
Changes in cystathionine levels in micromoles
Through double-blind study completion, approximately 10 months per patient
Changes in Met cycle metabolites levels - Phe (Cohorts 1-6 Only)
Tidsramme: Through double-blind study completion, approximately 10 months per patient
Changes in phenylalanine levels in micromoles
Through double-blind study completion, approximately 10 months per patient
Descriptive ophthalmology examination findings (Cohorts 1-6 Only)
Tidsramme: Through double-blind study completion, approximately 10 months per patient
Comprehensive ophthalmological examination (for each eye: visual acuity [myopia, hyperopia, exotropia], slit lamp examination [ectopic lentis, cataracts, corneal abrasion, and uveitis], retinal examination [retinal degeneration, retinal detachment, retinitis pigmentosa, uveitis)]). Assessment of presence and severity of findings.
Through double-blind study completion, approximately 10 months per patient
Bone densitometry using dual-energy X-ray absorptionmetry (DEXA) scans (Cohorts 1-6 Only)
Tidsramme: Through double-blind study completion, approximately 10 months per patient
Through double-blind study completion, approximately 10 months per patient
Cognitive assessments using the National Institutes of Health Toolbox Cognition Battery score (Cohorts 1-6 Only)
Tidsramme: Through double-blind study completion, approximately 10 months per patient
Through double-blind study completion, approximately 10 months per patient
Patient Reported Outcome (PRO): Quality of Life in Neurological Disorders [Neuro-QoL] (Cohorts 1-6 Only)
Tidsramme: Through double-blind study completion, approximately 10 months per patient
The Quality of Life in Neurological Disorders [Neuro-QoL] includes Anxiety Short Form, Depression Short Form, Satisfaction with Social Roles Short Form, Cognition Function Short Form for 18+ years of age; Anxiety Short Form, Depression Short Form, Social Relations - Interaction with Peers Short Form, and Cognitive Function Short Form for Ages 12 to 17 years old
Through double-blind study completion, approximately 10 months per patient
Patient Reported Outcome (PRO): Quality of Life by 36-Item Short Form Survey [SF-36] (Cohorts 1-6 Only)
Tidsramme: Through double-blind study completion, approximately 10 months per patient
Through double-blind study completion, approximately 10 months per patient
Patient Reported Outcome (PRO): Quality of Life by EuroQol 5-Dimentional Instrument [EQ 5D] (Cohorts 1-6 Only)
Tidsramme: Through double-blind study completion, approximately 10 months per patient
Through double-blind study completion, approximately 10 months per patient

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Etterforskere

  • Studieleder: Michael Imperiale, MD, Travere Therapeutics, Inc.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

22. januar 2019

Primær fullføring (Antatt)

1. juli 2027

Studiet fullført (Antatt)

1. juli 2027

Datoer for studieregistrering

Først innsendt

5. desember 2017

Først innsendt som oppfylte QC-kriteriene

15. januar 2018

Først lagt ut (Faktiske)

23. januar 2018

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

10. august 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

5. august 2026

Sist bekreftet

1. juli 2026

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • CBS-HCY-CT-01

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

JA

IPD-planbeskrivelse

Forespørsler om kliniske forsøksdata, inkludert språk som angir tiltenkt bruk, skal rettes til datarequest@travere.com. Hvis den godkjennes, vil den forespurte informasjonen bli gitt til rekvirenten etter signering av en datatilgangsavtale. Forespørsler kan fremsettes etter fullføring av studien og full publisering av studiedataene i et fagfellevurdert tidsskrift i opptil 36 måneder etter publiseringen. Travere forbeholder seg retten til å avslå eller anbefale endringer i en forespørsel hvis den ikke er i samsvar med retningslinjene for datadeling eller hvis det fastslås at forespørselen er gjort av en partisk kilde.

IPD-delingstidsramme

Forespørsler kan fremsettes etter fullføring av studien og full publisering av studiedataene i et fagfellevurdert tidsskrift i opptil 36 måneder etter publiseringen.

Tilgangskriterier for IPD-deling

Krever innsending og godkjenning av tiltenkt bruk og en datadelingsavtale.

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Ja

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

produkt produsert i og eksportert fra USA

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .